ArticleAllergy, asthma & immunology research2026
Comprehensive Study of Drug-Associated Severe Allergic Reactions: An Analysis of High-Risk Medications and Epidemiological Trends Based on the FAERS Database.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeDrug-induced anaphylactic shock (DIAS) is a severe adverse drug reaction. This study aimed to identify drugs significantly associated with DIAS through the real-time updated analysis of large-sample data.
methodsThis retrospective cohort study analyzed 20,748,017 adverse event reports from the Food and Drug Administration Adverse Event Reporting System database spanning from the first quarter of 2004 to the fourth quarter of 2023 to identify the main drugs causing anaphylactic shock. Descriptive statistical analysis was used to report the basic characteristics, while disproportionality analysis was employed to assess the correlation between specific drugs and DIAS events using metrics such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), and χ² test values. Additionally, detailed descriptive analyses were performed to examine yearly trends, sex and age distributions, and the sources and countries of reported DIAS events.
resultsThere were a total of 21,073 DIAS events, accounting for 0.10% of all reports. The median weight of the DIAS patients was 70 kg, the median age was 55 years, and the incidence of DIAS was significantly higher among females (56.57%) than among males (35.24%). DIAS was primarily associated with indications such as anesthesia, sclerosis, and arthritis. The top 10 drugs most strongly associated with anaphylactic shock were amoxicillin, propofol, moxifloxacin, infliximab, omalizumab, carboplatin, paclitaxel, cefuroxime, ceftriaxone, natalizumab, and rocuronium bromide. Asymmetric analysis revealed that the top 10 drugs with the strongest signals were remifentanil, carboplatin, propofol, ceftriaxone, iopromide, atracurium, meloxicam, cefuroxime, desflurane, and ringer lactate. (all ROR > 3, PRR > 2, χ² > 4,
conclusionsAntibiotics, anesthetics, monoclonal antibodies (mAbs), and antitumor drugs are the main categories of drugs associated with anaphylactic shock. Specifically, high clinical vigilance should be given to β-lactam antibiotics, intravenous anesthetics, antitumor drugs, and mAbs. Future research on DIAS should further explore its mechanisms, evaluate risk factors, and develop effective prevention strategies to enhance the safety and efficacy of drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.